Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective

Urology

Volumn 85, Issue 4, 2015, Pages 717-724

  Shore, Neal D ^a  

^a Carolina Urologic Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; GLUCOCORTICOID; KETOCONAZOLE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; ANTINEOPLASTIC AGENT; RADIOISOTOPE; RADIUM;

ANALGESIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; CLINICAL STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME; UROLOGIST; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); HEALTH PERSONNEL ATTITUDE; MALE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; UROLOGY;

ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIUM; UROLOGY;

EID: 84929940756     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.11.031     Document Type: Review

References (31)

1. Cancer of the Prostate - SEER Stat Fact Sheet. http://seer.cancer.gov/statfacts/html/prost.html.
2. K.N. Chi, A. Bjartell, D. Dearnaley et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets Eur Urol 56 2009 594 605
3. N. Sathiakumar, E. Delzell, M.A. Morrisey et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006 Prostate Cancer Prostatic Dis 14 2011 177 183
4. K. Fizazi, M. Carducci, M. Smith et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
5. C.J. Logothetis, E. Basch, A. Molina et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
6. F. Saad, D.M. Gleason, R. Murray et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
7. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer - v2 2014 Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
8. G. Henriksen, D.R. Fisher, J.C. Roeske et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice J Nucl Med 44 2003 252 259
9. R.B. Den, L.A. Doyle, K.E. Knudsen Practical guide to the use of radium 223 dichloride Can J Urol 21 2 Suppl 1 2014 70 76
10. H. Jadvar, D.I. Quinn Targeted alpha-particle therapy of bone metastases in prostate cancer Clin Nucl Med 38 2013 966 971
11. K.A. Autio, H.I. Scher, M.J. Morris Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer Curr Treat Options Oncol 13 2012 174 188
12. S. Nilsson, R.H. Larsen, S.D. Fossa et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 2005 4451 4459
13. O.S. Bruland, S. Nilsson, D.R. Fisher, R.H. Larsen High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12 20 Pt 2 2006 6250s 6257s
14. C.C. Parker, S. Pascoe, A. Chodacki et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer Eur Urol 63 2013 189 197
15. S. Nilsson, P. Strang, A.K. Aksnes et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer Eur J Cancer 48 2012 678 686
16. S. Nilsson, L. Franzen, C. Parker et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594
17. C. Parker, S. Nilsson, D. Heinrich et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
18. O. Sartor, R. Coleman, S. Nilsson et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial Lancet Oncol 15 2014 738 746
19. M. Tomblyn, S. Nilsson, N. Vogelzang et al. Pain and quality of life (QoL) analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases J Urol 189 2013 e293
20. Nilsson S, Vogelzang N, Sartor O, et al. 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study. Poster presented at: 2014 Genitourinary Cancers Symposium, January 30-February 1, 2014, San Francisco, California.
21. Morris MJ, Hammers H-J, Sweeney C, et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I Prostate Cancer Clinical Trials Consortium Study. Presented at: ASCO Annual Meeting, May 31-June 4, 2013, Chicago, Illinois.
22. Xofigo (radium Ra 223 dichloride) Injection, for Intravenous Use [Package Insert] May 2013 Bayer HealthCare Pharmaceuticals Inc Wayne NJ
23. A. Omlin, C. Pezaro, S. Gillessen Sommer Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy Ther Adv Urol 6 2014 3 14
24. T.M. Beer, A.J. Armstrong, D.E. Rathkopf et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
25. Vogelzang NJ, Helle SI, Johannessen DC, et al. Efficacy and safety of radium dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial. Presented at: ASCO Annual Meeting, May 31-June 4, 2013, Chicago, Illinois.
26. M.S. Cookson, B.J. Roth, P. Dahm et al. Castration-resistant Prostate Cancer: AUA Guideline 2014 American Urological Association Linthicum, MD
27. J.M. Fitzpatrick, J. Bellmunt, K. Fizazi et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel Eur J Cancer 50 2014 1617 1627
28. O'Sullivan JM, Johannessen DC, Widmark A, et al. Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: baseline prognostic factor subgroup analysis. Poster presented at: 24th International Prostate Cancer Update, February 19-22, 2014, Vail, Colorado. 2014.
29. H.I. Scher, S. Halabi, I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
30. J. Hoffman-Censits, W.K. Kelly Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer Clin Cancer Res 19 2013 1335 1339
31. J.S. de Bono, C.J. Logothetis, A. Molina et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005